CoChat
Sign Up
Cited by 81

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Cerebrospinal fluid/plasma albumin ratio as a biomarker for blood-brain barrier impairment across neurodegenerative dementias.

Musaeus, Christian Sandøe, Gleerup, Helena Sophia, Høgh, Peter, Waldemar, Gunhild, Hasselbalch, Steen Gregers, Simonsen, Anja Hviid·2020·Journal of Alzheimer's Disease
DOI 10.3233/jad-200168
Open this paper in CoChat — free account

Abstract

Background Previous studies have shown an association between disruption of the blood-brain-barrier (BBB) and dementias of different etiologies. The protein concentration of cerebrospinal fluid (CSF) can be used as an indirect measurement for the permeability of the BBB using the CSF/plasma albumin quotient (Q-Alb) or total CSF protein. Objective In the current study, we wanted to investigate Q-Alb and CSF protein concentration in dementias of different etiologies and the possible confounding factors. Methods A total of 510 patients and healthy controls were included in the current study. The patients were diagnosed with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), vascular dementia (VaD), or frontotemporal dementia (FTD). Results We found that Q-Alb was significantly different between the groups (p = 0.002, F = 3.874). Patients with DLB and VaD showed the largest Q-Alb. Although not significant for CSF total protein, we found the same overall pattern for DLB and VaD. When examining confounding factors, we found a positive association with age and a lower Fazekas score in DLB as compared to VaD. Conclusion These results suggest that Q-Alb can contribute to our understanding of the pathophysiological mechanisms in DLB, and Q-Alb may serve as a supplementary diagnostic marker. Furthermore, we found a positive association with age, which may be due to differences in vascular co-morbidities. In addition, in patients with DLB, the increased Q-Alb is not due to vascul…

Overview

Integrity signals

Registry

Crossref · 10.3233/jad-200168

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Blood Brain Barrier becomes leaky with age and serum albumin crosses it and is found in cerebro-spinal-fluid of older individuals in positive correlation with age and certain types of dementias.

    “With respect to reaching neural cells in vivo, Blood Brain Barrier becomes leaky with age [31, 32] and serum albumin crosses it and is found in cerebro-spinal-fluid of older individuals in a positive correlation with age and with certain types of dementias [33].”

    From Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin (2020) · cites this paper as [33]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. Skillback, 2017, CSF/serum albumin ratio in dementias: A cross-sectional study on 1861 patients, Neurobiol Aging, 59, 1, 10.1016/j.neurobiolaging.2017.06.028 · DOI
  2. Sweeney, 2018, Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders, Nat Rev Neurol, 14, 133, 10.1038/nrneurol.2017.188 · DOI · Paper page
  3. Felgenhauer, 1977, Hydrodynamic radii versus molecular weights in clearance studies of urine and cerebrospinal fluid, Ann Clin Biochem, 14, 100, 10.1177/000456327701400118 · DOI
  4. Llorens, 2015, Increased albumin CSF/serum ratio in dementia with Lewy bodies, J Neurol Sci, 358, 398, 10.1016/j.jns.2015.10.011 · DOI
  5. Palm, 1986, Zinc, total protein, and albumin in CSF of patients with cerebrovascular diseases, Acta Neurol Scand, 74, 308, 10.1111/j.1600-0404.1986.tb03520.x · DOI
  6. Skoog, 1998, A population study on blood-brain barrier function in 85-year-olds: Relation to Alzheimer’s disease and vascular dementia, Neurology, 50, 966, 10.1212/WNL.50.4.966 · DOI
  7. Janelidze, 2017, Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype, Neurobiol Aging, 51, 104, 10.1016/j.neurobiolaging.2016.11.017 · DOI · Paper page
  8. Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis, Lancet Neurol, 15, 673, 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
  9. Chalbot, 2011, Blood-cerebrospinal fluid barrier permeability in Alzheimer’s disease, J Alzheimers Dis, 25, 505, 10.3233/JAD-2011-101959 · DOI
  10. Sundelof, 2010, Higher cathepsin B levels in plasma in Alzheimer’s disease compared to healthy controls, J Alzheimers Dis, 22, 1223, 10.3233/JAD-2010-101023 · DOI
  11. Seyfert, 2002, Determinants of lumbar CSF protein concentration, J Neurol, 249, 1021, 10.1007/s00415-002-0777-2 · DOI
  12. Musaeus, 2019, Microstates as disease and progression markers in patients with mild cognitive impairment, Front Neurosci, 13, 563, 10.3389/fnins.2019.00563 · DOI
  13. Schjonning Nielsen, 2018, Quantitative electroencephalography analyzed by statistical pattern recognition as a diagnostic and prognostic tool in mild cognitive impairment: Results from a Nordic multicenter cohort study, Dement Geriatr Cogn Dis Extra, 8, 426, 10.1159/000490788 · DOI · Paper page
  14. McKhann, 2011, The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 263, 10.1016/j.jalz.2011.03.005 · DOI · Paper page
  15. McKhann, 1984, Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  16. Roman, 1993, Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop, Neurology, 43, 250, 10.1212/WNL.43.2.250 · DOI · Paper page
  17. Rascovsky, 2011, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 2456, 10.1093/brain/awr179 · DOI · Paper page
  18. McKhann, 2001, Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick’s Disease, Arch Neurol, 58, 1803, 10.1001/archneur.58.11.1803 · DOI
  19. Gorno-Tempini, 2011, Classification of primary progressive aphasia and its variants, Neurology, 76, 1006, 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
  20. Parrado-Fern ández, 2018, Evidence for sex difference in the CSF/plasma albumin ratio in 20 000 patients and 335 healthy volunteers, J Cell Mol Med, 22, 5151, 10.1111/jcmm.13767 · DOI
  21. Capouch, 2018, A review of dementia with Lewy bodies’ impact, diagnostic criteria and treatment, Neurol Ther, 7, 249, 10.1007/s40120-018-0104-1 · DOI
  22. Uversky, 2002, Accelerated alpha-synuclein fibrillation in crowded milieu, FEBS Lett, 515, 99, 10.1016/S0014-5793(02)02446-8 · DOI
  23. Munishkina, 2004, The effect of macromolecular crowding on protein aggregation and amyloid fibril formation, J Mol Recognit, 17, 456, 10.1002/jmr.699 · DOI
  24. Bellomo, 2019, Dissecting the interactions between human serum albumin and alpha-synuclein: New insights on the factors influencing alha-synuclein aggregation in biological fluids, J Phys Chem B, 123, 4380, 10.1021/acs.jpcb.9b02381 · DOI
  25. Kakinen, 2018, Serum albumin impedes the amyloid aggregation and hemolysis of human islet amyloid polypeptide and alpha synuclein, Biochim Biophys Acta Biomembr, 1860, 803, 10.1016/j.bbamem.2018.01.015 · DOI
  26. 10.21037/jlpm.2018.03.12 · DOI
  27. Thompson, 1988, The CSF proteins: A biochemical approach
  28. Farrall, 2009, Blood-brain barrier: Ageing and microvascular disease–systematic review and meta-analysis, Neurobiol Aging, 30, 337, 10.1016/j.neurobiolaging.2007.07.015 · DOI · Paper page
  29. Miners, 2019, CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology, Alzheimers Res Ther, 11, 81, 10.1186/s13195-019-0534-8 · DOI
  30. Sakib, 2019, The prevalence of multimorbidity and associations with lifestyle factors among middle-aged Canadians: An analysis of Canadian Longitudinal Study on Aging data, BMC Public Health, 19, 243, 10.1186/s12889-019-6567-x · DOI
  31. Eeg-Olofsson, 1981, Concentrations of CSF proteins as a measure of blood brain barrier function and synthesis of IgG within the CNS in ‘normal’ subjects from the age of 6 months to 30 years, Acta Paediatr Scand, 70, 167, 10.1111/j.1651-2227.1981.tb05536.x · DOI
  32. Hegen, 2016, Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: Implications for increased clinical specificity, Clin Chem Lab Med, 54, 285, 10.1515/cclm-2015-0253 · DOI
  33. Shalev, 2009, Breaching the blood-brain barrier as a gate to psychiatric disorder, Cardiovasc Psychiatry Neurol, 2009, 278531, 10.1155/2009/278531 · DOI
  34. Gudmundsson, 2007, The relationship between cerebrospinal fluid biomarkers and depression in elderly women, Am J Geriatr Psychiatry, 15, 832, 10.1097/JGP.0b013e3180547091 · DOI

Cited by

Sorted by citations

Metadata

Authors
Musaeus, C. S., Gleerup, H. S., Høgh, P., Waldemar, G., Hasselbalch, S. G., & Simonsen, A. H.
Affiliations
  • Department of Neurology, Danish Dementia Research Centre (DDRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
  • Regional Dementia Research Centre, Department of Neurology, Zealand University Hospital, Roskilde, Denmark
Venue
Journal of Alzheimer's Disease
Publisher
SAGE Publications
Published
2020-05-19
Volume
75
Issue
2
Pages
429-436
ISSN
  • 1387-2877
  • 1875-8908
DOI
10.3233/jad-200168
Cited by
81
References
7

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review